SEC For																			
	FORM	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP												OMB APPROVAL OMB Number: 3235-0287					
Check this box if no longer subject to STATE Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					ed pui	rsuant	t to Secti	on 16(a)	of the Secu	11F		ated av	erage burder ponse:	ו 0.5					
1. Name and Address of Reporting Person [*] Siegel Jolie						2. Issuer Name and Ticker or Trading Symbol <u>C4 Therapeutics, Inc.</u> [CCCC]								lationship of ck all applica Director	able)	10% Owner			
(Last) C/O C4	st) (First) (Middle) O C4 THERAPEUTICS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 03/07/2024								X	X Officer (give title Other (specify below) below) Chief Legal Officer					
490 ARSENAL WAY #120				4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) WATER	FOWN M	02472								X	X Form filed by One Reporting Person Form filed by More than One Reportin Person								
(City)	(5	(Zip)			Rule 10b5-1(c) Transaction Indication														
						the a	ck this bo: affirmative	x to indica defense (te that a trans conditions of	Rule	on was mac 10b5-1(c).	See Instruct	to a contrac ion 10.	t, instruction c	or written pl	lan that	is intended t	o satisfy	
			able I - Noi					-	1	- T				1					
Date				Date	insaction th/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Code (Instr.		4. Securitie Disposed C	es Acquired (A) or Of (D) (Instr. 3, 4 and 5)		5. Amount Securities Beneficial Owned Fo Reported	ly	Form	Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code V	/	Amount	(A) or (D)	Price	Transactio (Instr. 3 ar	ction(s)			(1130. 4)	
			Table II -						ired, Dis options,					Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exe Expiration (Month/Day	ercisa Date	isable and 7. Title an of Securit		d Amount ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Co	ode	v	(A) (D) Date Expiration Date Title Shares			(Instr. 4)									
Stock Option (Right to Buy)	\$45.54	03/07/2024		D)(1)	84,850		(2)	0	02/10/2031	Common Stock	84,850	\$0 ⁽¹⁾	0		D			
Stock Option (Right to Buy)	\$19	03/07/2024		А	(1)	1) 84,850		(2)		02/10/2031	Common Stock	84,850	\$0 ⁽¹⁾	84,85	50	D			
Stock Option (Right to Buy)	\$22.71	03/07/2024		D) (1)			90,000	(3)	0	02/13/2032	Common Stock	90,000	\$0 ⁽¹⁾	0		D		
Stock Option (Right to Buy)	\$19	03/07/2024		А	(1)		90,000		(3)	0	02/13/2032	Common Stock	90,000	\$0 ⁽¹⁾	90,00	00	D		

Explanation of Responses:

1. On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

2. This option shall vest and become exercisable in 16 equal quarterly installments, with the first installment vesting on May 11, 2021.

3. The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022.

Remarks:

/s/ Jolie M. Siegel

** Signature of Reporting Person

03/08/2024 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.